Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 19;20(12):91.
doi: 10.1007/s11864-019-0686-6.

Opioid-Induced Constipation in Oncological Patients: New Strategies of Management

Affiliations
Review

Opioid-Induced Constipation in Oncological Patients: New Strategies of Management

Ricard Mesía et al. Curr Treat Options Oncol. .

Abstract

Cancer-associated pain has traditionally been treated with opioid analgesics, often in escalating doses. Opioid-induced constipation (OIC) is a common problem associated with chronic use of opioid analgesics. Typical treatment strategies to alleviate constipation are based on dietary changes, exercise, and laxatives. However, laxatives have a nonspecific action and do not target underlying mechanisms of OIC. This article will review prevalent, clinical presentation and recommendations for the treatment of OIC. An independent literature search was carried out by the authors. We reviewed the literature for randomized controlled trials that studied the efficacy of laxatives, naloxone, and naloxegol in treating OIC. Newer strategies addressing the causal pathophysiology of OIC are needed for a more effective assessment and management of OIC. Finally, traditional recommended therapies are appraised and compared with the latest pharmacological developments. Future research should address whether naloxegol is more efficacious by its comparison directly with first-line treatments, including laxatives.

Keywords: Cancer; Laxatives; Naloxegol; Opioid analgesics; Opioid-induced constipation; Pain.

PubMed Disclaimer

Conflict of interest statement

Ricard Mesía has received compensation from Merck, Bristol-Myers Squibb, MSD, Kyowa, AstraZeneca, Nanobiotix, and Roche for Service as a consultant. Juan Antonio Virizuela declares that he has no conflict of interest. Jose Gómez declares that he has no conflict of interest. Tamara Sauri declares that she has no conflict of interest. Gloria Serrano declares that she has no conflict of interest. Eduardo Pujol declares that he has no conflict of interest.

This work was supported by Kyowa Kirin Farmaceutica SLU. The authors received research funding from Kyowa Kirin Farmaceutica SLU for this colaboration.

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Escobar Álvarez Y, Rodríguez Sánchez CA, Caballero Martínez F, Recuero Cuervo V, Camps Herrero C. Professional survey on knowledge and clinical patterns of pain management in Spanish medical oncology. Clin Transl Oncol. 2010;12(12):819–824. - PubMed
    1. Porta-Sales J, Nabal-Vicuna M, Vallano A, Espinosa J, Planas-Domingo J, Verger-Fransoy E, Julià-Torras J, Serna J, Pascual-López A, Rodríguez D, Grimau I, Morlans G, Sala-Rovira C, Calsina-Berna A, Borras-Andrés JM, Gomez-Batiste X. Have we improved pain control in cancer patients? A multicenter study of ambulatory and hospitalized cancer patients. J Palliat Med. 2015;18(11):923–932. - PubMed
    1. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1) Pain Med. 2009;10:35–42. - PubMed
    1. Larkin PJ, Cherny NI, La Carpia D, Guglielmo M, Ostgathe C, Scotté F, Ripamonti CI. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29:iv111–iv125. - PubMed
    1. Brenner DM, Stern E, Cash BD. Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep. 2017;19(3):12. - PubMed

Publication types

MeSH terms

Substances